Moreover, in vivo study using a glioma-bearing mice model showed an increase in the median survival rate (medium survival time of 53 days) and a decrease in tumor size when D-T7 peptide-modified co-loaded nanoparticles were compared with paclitaxel-loaded nanoparticles (medium survival time of 32 days) and cediranib-loaded nanoparticles (medium survival time of 38 days), suggesting the potential of combining a VEGFR inhibitor and a chemotherapeutic agent in a target nanosystem to improve glioma therapy [86]. Here, KDR is linked to glioma.